On December 18, 2025, Werewolf Therapeutics, Inc. (NASDAQ:HOWL) shared a comprehensive pipeline update in which it highlighted clinical progress and 2026 priorities for its INDUKINE programs and ...
I visited an Illinois wolf sanctuary where the howls stop you cold. Real rescues, quiet moments, and a visit that lingers long after—with wolves.
Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...
Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...
Director Luke Evnin reported selling shares of Werewolf Therapeutics Inc (NASDAQ:HOWL), a micro-cap biotech company valued at just $31.07 million, in three separate transactions, with the total value ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results